Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trolamine SCHEMBL434089 | 0.88 | MAPT (0.47) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| Trolamine SCHEMBL4748243 | 0.88 | MAPT (0.47) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| Trolamine SCHEMBL15845959 | 0.88 | MAPT (0.47) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| Trolamine SCHEMBL1146 | 0.88 | MAPT (0.47) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| SCHEMBL23528233 | 0.84 | MAPT (0.46) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| Trolamine SCHEMBL565435 | 0.84 | MAPT (0.44) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| Trolamine SCHEMBL6516752 | 0.84 | MAPT (0.44) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| Trolamine SCHEMBL5862137 | 0.84 | MAPT (0.44) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| Trolamine SCHEMBL5934922 | 0.84 | MAPT (0.44) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 | |
| Trolamine SCHEMBL9113868 | 0.84 | MAPT (0.44) | MAPTKDM4EALOX15SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5554213-A | AMMONIUM OR AMINE PHOSPHONATE SALT | XEROX CORPORATION (US) | 1996-09-10 | — | — | US | claimed |
| CN-107614472-A | The manufacture method and packing method of hydroxyl substituted aromatic compound | 三菱瓦斯化学株式会社 | 2018-01-19 | — | — | CN | disclosed |
| US-7858661-B2 | Protein refolding agent and refolding method | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20100168403-A1 | Protein refolding agent and refolding method | YAMAGUCHI SHUNICHLRO | 2010-07-01 | — | — | US | disclosed |
| US-20090111971-A1 | PROTEIN REFOLDING AGENT AND REFOLDING METHOD | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-5554213-A | AMMONIUM OR AMINE PHOSPHONATE SALT | XEROX CORPORATION (US) | 1996-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111971-A1 | PROTEIN REFOLDING AGENT AND REFOLDING METHOD | HSPA5, HSPBP1, RRBP1 | MAPT 440/4885KDM4E 4403/4885ALOX15 3107/4885 |
| US-20100168403-A1 | Protein refolding agent and refolding method | HSPA5, HSPBP1, RRBP1 | MAPT 458/4885KDM4E 4398/4885ALOX15 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.